title: Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
abstract: OBJECTIVE
  To compare the effectiveness of the ternary-drug combination of colestipol, niacin, and lovastatin with binary combinations of those drugs in treating patients with familial hypercholesterolemia.
  
  
  METHODS
  An open sequential study of serum lipoprotein responses in patients receiving diet alone (mean duration, 4 months); colestipol and niacin with diet (mean duration, 9 months); and colestipol, niacin, and lovastatin with diet (mean duration, 15 months).
  
  
  METHODS
  Metabolic ward and lipid clinic of a university medical center.
  
  
  METHODS
  Twenty-two patients with clinical characteristics of familial hypercholesterolemia (low-density-lipoprotein cholesterol, greater than 8.48 mmol/L; 21 of 22 with tendon xanthomas).
  
  
  METHODS
  Diet: less than 200 mg/d of cholesterol and less than 8% of total calories from saturated fat; colestipol, 30 g/d; lovastatin, 40 to 60 mg/d; and niacin, 1.5 to 7.5 g/d.
  
  
  RESULTS
  Mean total serum cholesterol and low-density-lipoprotein cholesterol levels of 4.86 +/- 0.62 mmol/L (188 +/- 24 mg/dL SD) and 2.89 +/- 0.54 mmol/L (112 +/- 21 mg/dL SD), respectively, were significantly lower during ternary-drug treatment than during colestipol-niacin treatment (p less than 0.003) or during treatment in which other possible binary combinations were given. The cholesterol content of very low-density-lipoproteins was lower and high-density-lipoprotein cholesterol levels higher during this phase than during the colestipol-niacin phase.
  
  
  CONCLUSIONS
  Colestipol, lovastatin, and niacin are mutually complementary in treating hypercholesterolemia. This regimen produces reductions in serum cholesterol levels similar to those associated with regression of atheromatous plaques in animal studies.
authors: Cardiovascular Research Institute, University of California, San Francisco.
authors: M J
authors: MJ
authors: Malloy
authors: J P
authors: JP
authors: Kane
authors: S T
authors: ST
authors: Kunitake
authors: P
authors: P
authors: Tun
mesh_terms: D000328:Adult; D000368:Aged; D001055:Apolipoproteins B / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003084:Colestipol / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000235:genetics; D008148:Lovastatin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000008:administration & dosage*; D011073:Polyamines / Q000008:administration & dosage*
chemical_list: D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D011073:Polyamines; D009525:Niacin; D002784:Cholesterol; D008148:Lovastatin; D003084:Colestipol